SYNAGEVA BIOPHARMA CORP's ticker is GEVA and the CUSIP is 87159A103. A total of 97 filers reported holding SYNAGEVA BIOPHARMA CORP in Q3 2013. The put-call ratio across all filers is 0.10 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2015 | $1,543,000 | +3.3% | 15,826 | -1.7% | 0.00% | 0.0% |
| Q4 2014 | $1,494,000 | -5.6% | 16,097 | -30.0% | 0.00% | 0.0% |
| Q3 2014 | $1,582,000 | -45.8% | 23,010 | -17.4% | 0.00% | 0.0% |
| Q2 2014 | $2,919,000 | +216.6% | 27,864 | +150.3% | 0.00% | – |
| Q1 2014 | $922,000 | -54.7% | 11,132 | -64.6% | 0.00% | -100.0% |
| Q4 2013 | $2,034,000 | +97.1% | 31,424 | +93.0% | 0.00% | – |
| Q3 2013 | $1,032,000 | +2.2% | 16,285 | -32.3% | 0.00% | -100.0% |
| Q2 2013 | $1,010,000 | – | 24,069 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Baker Brothers Advisors | 10,660,432 | $989,182,000 | 10.10% |
| BB BIOTECH AG | 1,130,476 | $104,897,000 | 3.40% |
| BLUE JAY CAPITAL MANAGEMENT, LLC | 80,000 | $7,423,000 | 3.31% |
| Opus Point Partners Management, LLC | 20,002 | $1,856,000 | 1.84% |
| COLUMBIA WANGER ASSET MANAGEMENT LLC | 3,847,094 | $356,972,000 | 1.77% |
| SECTORAL ASSET MANAGEMENT INC | 363,884 | $33,765,000 | 1.52% |
| Cormorant Asset Management, LP | 100,000 | $9,279,000 | 1.43% |
| Tekla Capital Management LLC | 223,020 | $20,694,000 | 0.97% |
| Lamond Capital Partners LLC | 15,390 | $1,428,000 | 0.94% |
| Squarepoint Ops LLC | 6,700 | $622,000 | 0.60% |